ARK生物基因科技革新主动型ETF ARKG 深 沪
交易中 10-02 10:19:28 美东时间
54.215
+1.045
+1.97%
华盛通- 最 高54.78
- 今 开54.14
- 成交量 68.00万股
- 最 低 53.48
- 昨 收 53.17
- 总市值 220.38万
- 52周最高 55.30
- 市盈率 静 --
- 换手率 1672.82%
- 52周最低 24.60
- 委 比 95.24%
- 总股本 4.07万
- 历史最高 114.7676
- 量 比 2.29
- 振 幅 2.44%
- 历史最低 11.9805
- 每 手 1
- 风险率 7.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股ETF日报 | GraniteShares每日2倍做多NBIS主动型ETF劲升14.79%，成交额1.48亿美元
GraniteShares每日2倍做多NBIS主动型ETF涨14.79%；Leverage Shares每日2倍做多NBIS主动型ETF涨14.74%；Tradr每日2倍做多NBIS主动型ETF涨14.70%
09-25 08:31
Muse一夜爆红！“木头姐”大手笔增持Meta，加码医疗与生物科技
当地时间9月22日，“木头姐”Cathie Wood旗下方舟投资（ARK Invest）公布的每日交易纪录显示，持股重心明显偏向大型AI平台与基因精准医疗，同时...
09-23 09:49
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood is doubling down on biotech, but investors looking beyond her ARK Genomic Revolution ETF (BATS:ARKG) have several other ways to gain exposure to the same companies. ARKG bought about $4.5 million of Ionis Pharmaceuticals Inc (NASDAQ:IONS), nearly $3 million of Veracyte Inc (NASDAQ:VCYT),...
09-22 22:40
美股知名投资人最新调仓曝光：“木头姐”大举买入Meta，同时减持CrowdStrike
“木头姐”凯茜·伍德旗下ARK Invest公布9月21日交易记录，当天最受关注的操作是大举买入Meta，同时减持CrowdStrike，并继续调整医疗科技...
09-22 14:42
美股ETF日报 | 2倍做多Coinbase ETF升逾11%，SEC批准代币化股票交易“创新豁免”；2倍做多英伟达ETF升约5%，英伟达再加码AI基建
2倍做多Coinbase ETF升逾11%，SEC批准代币化股票交易“创新豁免”；2倍做多英伟达ETF升约5%，英伟达再加码AI基建>>
09-18 18:45
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc’s (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs. Their intismeran autogene therapy...
09-02 00:25
美股ETF日报 | 比特币突破7万美元！2倍做多Coinbase ETF升逾18%；2倍做多黄金ETF升逾7.5%
美债降息预期叠加SEC新规，比特币突破7万美元！2倍做多Coinbase ETF升逾18%；金价一度突破4500美元创2月新高，2倍做多黄金ETF升逾7.5%>>
08-20 17:26
Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
Moderna Inc.’s (NASDAQ:MRNA) latest cancer-vaccine breakthrough could be doing more than sending its stock sharply higher. It may be giving investors a reason to revisit an mRNA investment thesis that has largely been defined by COVID-19. ETFs tied to precision medicine names are also getting a boos...
08-20 05:49
